# A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Source: https://onco.cc/trials/nct07331155/  
OnCo record `nct07331155` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cisplatin, Tislelizumab and Capecitabine in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.

## Summary

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] is a phase 2 interventional study registered as NCT07331155 by Nanjing Leads Biolabs Co.,Ltd, with 110 participants planned, started 2026-02-26 and due to reach its primary completion in 2028-12-26. Interventions recorded: LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection, Tislelizumab Injection, 5-Fluorouracil injection and Capecitabine tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07331155
- Phase: 2
- Setting: An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour[Substudy Number 03(ESCC)]
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT07331155: https://clinicaltrials.gov/study/NCT07331155

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct07331155.json